References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-205-9-171-182

nogr-2054

Research Article

ОБЗОР

REVIEW

Рак поджелудочной железы, панкреатогенный диабет, сахарный диабет 2 типа

Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus

https://orcid.org/0000-0001-8317-7765

Друк

Инна Викторовна

Druk

I. V.

drukinna@yandex.ru

ФГБОУ ВО «Омский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияOmsk State Medical UniversityRussian Federation

2022

07102022

09171182

2022

Друк И.В.

Druk I.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2054

Рак поджелудочной железы (РПЖ) является четвертой ведущей причиной смерти среди всех видов рака. РПЖ очень агрессивен с низкой 5-летней общей выживаемостью. Наиболее высокая распространенность сахарного диабет (СД), существенно превышающая среднепопуляционную, регистрируется среди пациентов с РПЖ Рекомендации по системному скринингу пациентов с диабетом для выявления РПЖ не стандартизированы. Цель настоящего обзора - представить анализ современных литературных данных о патогенетических взаимосвязях между СД и РПЖ и перспективах скрининга РПЖ. Данные исследований свидетельствуют, что существует двунаправленная связь между СД и РПЖ, при которой СД может выступать либо как фактор риска РПЖ, либо как маркер паранеопластического синдрома РПЖ. В дифференциальной диагностике СД2 типа, панкреатогенного диабета и диабета, асоциированного с РПЖ, можно использовать комплекс клинических признаков. Пациенты с СД, имеющие дополнительные признаки/симптомы повышенного риска могут рассматриваться как группа, подлежащая обязательному скринингу. Опубликовано множество исследований различных протеомных, метаболомных, генетических и траскриптомных биомаркеров. Поиск простого в использовании клинически полезного и экономически эффективного маркера РПЖ все еще продолжается.

Pancreatic cancer (PC) is the fourth leading cause of death among all types of cancer. PC is very aggressive with a low 5-year overall survival rate. The highest prevalence of diabetes mellitus (DM), significantly exceeding the average population, is registered among patients with prostate cancer Recommendations for systemic screening of patients with diabetes for the detection of PC are not standardized. The purpose of this review is to present an analysis of current literature data on pathogenetic relationships between DM and PC and prospects for PC screening. Research data indicate that there is a bidirectional relationship between DM and PC, in which DM can act either as a risk factor for PC or as a marker of paraneoplastic syndrome of PC. In the differential diagnosis of type 2 diabetes, pancreatogenic diabetes and diabetes associated with PC, a set of clinical signs can be used. Patients with DM who have additional signs/symptoms of increased risk can be considered as a group subject to mandatory screening. Numerous studies of various proteomic, metabolomic, genetic and transcriptomic biomarkers PC have been published. The search for an easy-to-use clinically useful and cost-effective PC marker is still ongoing.

рак поджелудочной железысахарный диабетскринингбиомаркеры

pancreatic cancerdiabetes mellitusscreeningbiomarkers

References1

Rickels M.R., Norris A. W., Hull R. L. A tale of two pancreases: exocrine pathology and endocrine dysfunction. Diabetologia. 2020;63(10):2030-2039. doi:10.1007/s00125-020-05210-8

Ministry of Health of the Russian Federation. Clinical recommendations. Pancreatic cancer. (In Russian) Available: https://cr.minzdrav.gov.ru/recomend/355_1 (Accessed: 05.05.2021) @@Министерство здравоохранения Российской федерации. Клинические рекомендации. Рак поджелудочной железы. Available: https://cr.minzdrav.gov.ru/recomend/355_1

GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. Gastroenterology & hepatology. 2019;4(12): 934-947. doi:10.1016/S2468-1253(19)30347-4

Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27. doi:10.14740/wjon1166

Sung H., Ferlay J., Siegel R. L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

Satyananda V., Gupta R., Hari D. M., et al. Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed?. Gastroenterol Res Pract. 2019;2019:7690528. doi:10.1155/2019/7690528

Ose D.J., Viskochil R., Holowatyj A. N., et al. Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study. J Natl Compr Canc Netw. 2021;19(6):709-718. doi:10.6004/jnccn.2020.7653

Aggarwal G., Kamada P., Chari S. T. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013;42(2):198-201. doi:10.1097/MPA.0b013e3182592c96

Pergolini I., Schorn S., Jäger C., et al. Diabetes mellitus in intraductal papillary mucinous neoplasms: A systematic review and meta-analysis. Surgery. 2021;169(2):411-418. doi:10.1016/j.surg.2020.07.006

Woodmansey C., McGovern A.P., McCullough K.A., et al. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care. 2017;40(11):1486-1493. doi:10.2337/dc17-0542

Vujasinovic M., Zaletel J., Tepes B., et al. Low prevalence of exocrine pancreatic insufficiency in patients with diabetes mellitus. Pancreatology. 2013 Jul-Aug;13(4):343-6. doi:10.1016/j.pan.2013.05.010

Ewald N., Kaufmann C., Raspe A., Kloer H. U., Bretzel R. G., Hardt P. D. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28(4):338-42. doi:10.1002/dmrr.2260

Chari S.T., Leibson C. L., Rabe K. G., et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504-511. doi:10.1016/j.gastro.2005.05.007

Andersen D.K., Korc M., Petersen G. M., et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017;66(5):1103-1110. doi:10.2337/db16-1477

Roy A., Sahoo J., Kamalanathan S., et al. Diabetes and pancreatic cancer: Exploring the two-way traffic. World J Gastroenterol. 2021;27(30):4939-4962. doi:10.3748/wjg.v27.i30.4939

Yoon B.H., Ang S. M., Alabd A., et al. Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. J Surg Res. 2021;261:215-225. doi:10.1016/j.jss.2020.12.015

Perera C.J., Falasca M., Chari S. T., et al. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Cancers (Basel). 2021;13(20):5224. doi:10.3390/cancers13205224

Duan X., Wang W., Pan Q., Guo L. Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Front Oncol. 2021;11:730038. doi:10.3389/fonc.2021.730038

Muniraj T., Chari S. T. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012;58(4):331-345. PMID: 23207610; PMCID: PMC3932318.

Lee D.Y., Yu J. H., Park S., et al. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea. Sci Rep. 2018;8(1):9719. doi:10.1038/s41598-018-27965-2

Shahid R.K., Ahmed S., Le D., Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers (Basel). 2021;13(22):5735. doi:10.3390/cancers13225735

Scafoglio C., Hirayama B. A., Kepe V., et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015 28;112(30): E4111-9. doi:10.1073/pnas.1511698112

Sharma A., Chari S. T. Pancreatic Cancer and Diabetes Mellitus. Curr Treat Options Gastroenterol. 2018;16(4):466-478. doi:10.1007/s11938-018-0197-8

Sharma A., Kandlakunta H., Singh Nagpal S. J., et al. Model to Determine Risk of Pancreatic Cancer in Patients with New-onset Diabetes. Gastroenterology. 2018;155(3):730-739.e3. doi:10.1053/j.gastro.2018.05.023

Oldfield L., Evans A., Rao R. G., et al. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine. 2022;75:103802. doi:10.1016/j.ebiom.2021.103802

Sah R.P., Nagpal S. J., Mukhopadhyay D., Chari S. T. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423-433. doi:10.1038/nrgastro.2013.49

Permert J., Larsson J., Fruin A. B., et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas. 1997;15(1):60-8. doi:10.1097/00006676-199707000-00009

Hart P.A., Baichoo E., Bi Y., et al. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015; 15(2):162-6. doi:10.1016/j.pan.2015.02.006. Epub 2015

Liao W.C., Huang B. S., Yu Y. H., et al. Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer-Associated Diabetes. Diabetes Care. 2019;42(9):1752-1759. doi:10.2337/dc19-0217

El-Gohary, Yousef and Gittes, George (2018). Structure of Islets and Vascular Relationship to the Exocrine Pancreas. Pancreapedia: Exocrine Pancreas Knowledge Base. doi:10.3998/panc.2017.10

Longnecker Daniel S. 2021. Anatomy and Histology of the Pancreas. Pancreapedia: Exocrine Pancreas Knowledge Base. doi:10.3998/panc.2021.01

Dybala M. P., Kuznetsov A., Motobu M., et al.Integrated pancreatic blood flow: bi-directional microcirculation between endocrine and exocrine pancreas. Diabetes. 2020; 69(7):1439-1450. doi:10.2337/db19-1034

Chung K. M., Singh J., Lawres L., et al. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma. Cell. 2020; 181(4):832-847.e18. doi:10.1016/j.cell.2020.03.062

Pereira S. P., Oldfield L., Ney A., et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5(7):698-710. doi:10.1016/S2468-1253(19)30416-9

Stoffel E. M., McKernin S.E., Brand R., et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(2):153-164. doi:10.1200/JCO.18.01489

Takikawa T., Kikuta K., Kume K., et al. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer. Tohoku J Exp Med. 2020;252(4):353-364. doi:10.1620/tjem.252.353

Mizuno S., Nakai Y., Isayama H., et al. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. J Gastroenterol. 2013;48(2):238-46. doi:10.1007/s00535-012-0622-z

Bruenderman E. H., Martin R. C. 2nd. High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. J Surg Res. 2015;194(1):212-219. doi:10.1016/j.jss.2014.06.046

Sagami R., Sato T., Mizukami K., et al. Diagnostic Strategy of Early Stage Pancreatic Cancer via Clinical Predictor Assessment: Clinical Indicators, Risk Factors and Imaging Findings. Diagnostics (Basel). 2022;12(2):377. doi:10.3390/diagnostics12020377

Boursi B., Finkelman B., Giantonio B. J., et al. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology. 2017;152(4):840-850.e3. doi:10.1053/j.gastro.2016.11.046

Elbanna K. Y., Jang H. J., Kim T. K. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging. 2020. 25;11(1):58. doi:10.1186/s13244-020-00861-y

Syngal S., Brand R. E., Church J. M., et al. American College of Gastroenterology ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-262. doi:10.1038/ajg.2014.435

Ulrich C. D., Consensus Committees of the European Registry of Hereditary Pancreatic Diseases. Midwest Multi-Center Pancreatic Study Group, International Association of Pacreatology Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology. 2001;1(5):416-22. doi:10.1159/000055841

Rulyak S. J., Lowenfels A. B., Maisonneuve P., Brentnall T. A. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124(5):1292-9. doi:10.1016/s0016-5085(03)00272-5

Martín-Blázquez A., Jiménez-Luna C., Díaz C., et al. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Cancers (Basel). 2020;12(4):1002. doi:10.3390/cancers12041002

Cohen J.D., et al.Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci USA. 2017;114(38):10202-10207. doi:10.1073/pnas.1704961114

O’Brien D.P., Sandanayake N. S., Jenkinson C., et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 2015; 21: 622-31. doi:10.1158/1078-0432.CCR-14-0365

Kim J., Bamlet W. R., Oberg A. L., et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9(398): eaah5583. doi:10.1126/scitranslmed.aah5583

Jenkinson C., Elliott V. L., Evans A., et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clin Cancer Res. 2016;22(7):1734-1743. doi:10.1158/1078-0432.CCR-15-0879

Tanaka M., Heckler M., Liu B., et al. Cytologic analysis of pancreatic juice increases specificity of detection of malignant IPMN - a systematic review. Clin Gastroenterol Hepatol. 2019;17(11):2199-2211.e21. doi:10.1016/j.cgh.2018.12.034

Johansen J.S., Calatayud D., Albieri V., et al. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.Int J Cancer. 2016;139(10):2312-24. doi:10.1002/ijc.30291

Kang M., Qin W., Buya M., et al. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Cancer Lett. 2016;373(2):241-50. doi:10.1016/j.canlet.2015.12.031

Lee H.S., Jang C. Y., Kim S. A., et al.Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Sci Rep. 2018;8(1):3383. doi:10.1038/s41598-018-21823-x

Mellby L.D., Nyberg A. P., Johansen J. S., et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018; 36: 2887-94. doi:10.1200/JCO.2017.77.6658

Robinson M.R., Miller R. A., Spellman D. S. Mass Spectrometry-Based Biomarkers in Drug Development. Adv Exp Med Biol. 2019;1140:435-449. doi:10.1007/978-3-030-15950-4_25. PMID: 31347063.

Schrimpe-Rutledge A.C., Codreanu S. G., Sherrod S. D., McLean J. A. Untargeted Metabolomics Strategies-Challenges and Emerging Directions. J. Am. Soc. Mass Spectrom. 2016;27:1897-1905. doi:10.1007/s13361-016-1469-y

Cheung P.K., Ma M. H., Tse H. F., et al. The applications of metabolomics in the molecular diagnostics of cancer. Expert Rev. Mol. Diagn. 2019;19:785-793. doi:10.1080/14737159.2019.1656530

Roig B., Rodríguez-Balada M., Samino S., et al. Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer. Sci. Rep. 2017;7:17831. doi:10.1038/s41598-017-17897-8

Gu W., Tong Z. Clinical Application of Metabolomics in Pancreatic Diseases: A Mini-Review. Lab. Med. 2020;51:116-121. doi:10.1093/labmed/lmz046

Kamphorst J.J., Nofal M., Commisso C., et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75:544-553. doi:10.1158/0008-5472.CAN-14-2211

Tao L., Zhou J., Yuan C., et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabolomics. 2019;15:86. doi:10.1007/s11306-019-1550-1

Morin A., Letouzé E., Gimenez-Roqueplo A.P., Favier J. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.Int. J. Cancer. 2014;135:2237-2248. doi:10.1002/ijc.29080

Zhang L., Jin H., Guo X., et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1) H nuclear magnetic resonance-based metabonomic profiles. Clin. Biochem. 2012;45:1064-1109. doi:10.1016/j.clinbiochem.2012.05.012

Kobayashi T., Nishiumi S., Ikeda A., et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol.Biomarkers Prev. 2013;22:571-579. doi:10.1158/1055-9965.EPI-12-1033.

Michálková L., Horník Š., Sýkora J., et al. Diagnosis of pancreatic cancer via1H NMR metabolomics of human plasma. Analyst. 2018;143:5974-5978. doi:10.1039/C8AN01310A

Mayerle J., Kalthoff H., Reszka R., et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis [published correction appears in Gut. 2018;67(5):994]. Gut. 2018;67(1):128-137. doi:10.1136/gutjnl-2016-312432

Iwano T., Yoshimura K., Watanabe G., et al. High-performance Collective Biomarker from Liquid Biopsy for Diagnosis of Pancreatic Cancer Based on Mass Spectrometry and Machine Learning. J Cancer. 2021;12(24):7477-7487. doi:10.7150/jca.63244

Kleeff J., Korc M., Apte M., et al. Pancreatic cancer. Nat. Rev. Dis. Primers. 2016;2:1-22. doi:10.1038/nrdp.2016.22

Apte M.V., Wilson J. S., Lugea A., Pandol S. J. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013;144:1210-1219. doi:10.1053/j.gastro.2012.11.037

Apte M.V., Wilson J. S. A multipronged approach to pancreatic cancer treatment. Nat. Rev. Gastroenterol. Hepatol. 2016;13:385-387. doi:10.1038/nrgastro.2016.75

Melstrom L.G., Salazar M. D., Diamond D. J. The pancreatic cancer microenvironment: A true double agent. J Surg Oncol. 2017 Jul;116(1):7-15. doi:10.1002/jso.24643

Yan Y., Fu G., Ming L. Role of exosomes in pancreatic cancer. Oncol Lett. 2018;15(5):7479-7488. doi:10.3892/ol.2018.8348

Emmanouilidi A., Paladin D., Greening D. W., Falasca M. Oncogenic and Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis. Proteomics. 2019 Apr;19(8): e1800158. doi:10.1002/pmic.201800158

Zhang W., Xing J., Liu T., et al. Small extracellular vesicles: from mediating cancer cell metastasis to therapeutic value in pancreatic cancer. Cell Commun Signal. 2022;20(1):1. doi:10.1186/s12964-021-00806-y

Zhang H., Xing J., Dai Z., Wang D., et al. Exosomes: the key of sophisticated cell-cell communication and targeted metastasis in pancreatic cancer. Cell Commun Signal. 2022;20(1):9. doi:10.1186/s12964-021-00808-w

Li M., Guo H., Wang Q., et al. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Cancer Lett. 2020;490:20-30. doi:10.1016/j.canlet.2020.06.009

Sun W., Ren Y., Lu Z., Zhao X. The potential roles of exosomes in pancreatic cancer initiation and metastasis. Mol Cancer. 2020;19(1):135. doi:10.1186/s12943-020-01255-w

Waldenmaier M., Seibold T., Seufferlein T., Eiseler T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers (Basel). 2021;13(19):4844. doi:10.3390/cancers13194844

Korc M. Pancreatic cancer-associated diabetes is an “exosomopathy”. Clin Cancer Res. 2015;21(7):1508-10. doi:10.1158/1078-0432

Javeed N., Sagar G., Dutta S. K., et al. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction [published correction appears in Clin Cancer Res. 2015 Oct 1;21(19):4495]. Clin Cancer Res. 2015;21(7):1722-1733. doi:10.1158/1078-0432

Wang L., Zhang B., Zheng W., et al. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 2017;7(1):5384. doi:10.1038/s41598-017-05541-4

The authors declare that there are no conflicts of interest present.